Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, FDA

NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer

IRVINE, Calif., March 5, 2019 /PRNewswire/ -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for SNK01, an autologous NK cell adoptive immunotherapy candidate for the treatment of patients with pathologically confirmed cancer refractory to conventional therapy.

"We are very pleased to receive our first US IND approval to begin clinical trials in refractory cancer patients," said Paul Song, MD, CMO and CCO of NKMax America.  "While we collect our initial toxicity data, we are also preparing to submit additional IND applications for combination therapy in cancer as well as for several other non-cancerous diseases."

"Our innovative autologous NK cell technology allows us to expand NK cells from cancer patients," said Amber Kaplan, PhD, CSO of NKMax America.  "We are looking forward to advancing the program further into clinical trials."

SNK01 is an autologous therapy that is manufactured by harvesting a small number of a patient's immune cells.  After harvesting, the NK cells are separated from the blood, purified, activated, and expanded in our cGMP facility.  The activated NK cells are then injected back into the patient to fight against the cancer.

The IND approval allows NKMax America to initiate Phase I clinical trials to assess the safety and tolerability of SNK01 in adults with pathologically confirmed cancer refractory to conventional therapy. 

About NKMax America
NKMax America, Inc. is a biotech company specializing in both autologous and allogenic Natural Killer (NK) cell therapy utilizing our proprietary cell expansion and cell activation technology.  This therapeutic technology was developed as a complement to ATGen's first-in-kind in vitro diagnostic test which measures NK cell activity using only 1 ml blood.

For more information on the company, please visit www.nkmaxamerica.com


SOURCE NKMax America, Inc.

These press releases may also interest you

at 12:04
Patient enrollment is one of the most expensive and delicate aspects of a new clinical trial. Judi // Eligibility, the newest offering within AG Mednet's clinical trial SaaS platform, streamlines central eligibility review workflows in trials, and...

at 12:00
Global Vascular Embolization Devices Market: About this market This vascular embolization devices market analysis considers sales from both coiling and non-coiling devices. Our study also finds the sales of vascular embolization devices in Asia,...

at 12:00
Tremont Strategies Group (TSG), a Boston-based, bipartisan government relations firm, announced today that David Garriepy is joining the team as Vice President, Government Relations. David has over a decade of state and federal government relations...

at 11:49
Eligible producers from participating Land O'Lakes co-ops and direct Land O'Lakes Dairy members in Minnesota and Kansas have less than two weeks to enroll in the Land O'Lakes Cooperative Farmer Member Health Plan. For coverage beginning January 1,...

at 11:45
The "Global Digital Biomarkers Market: Focus on Key Trends, Growth Potential, Competitive Landscape, Components, End Users, Application (Sleep and Movement, Neuro, Respiratory and Cardiological Disorders) and Region - Analysis and Forecast,...

at 11:41
A recent study by the National Institute for Occupational Health and Safety revealed that cancer is currently the leading cause of death among firefighters. Recognizing the need for resources to support the brave men and women who put their lives on...

News published on 5 march 2019 at 14:56 and distributed by: